Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
MedCap AB (publ) is a Swedish investment company focused on acquiring and developing profitable, market-leading niche companies in the life science industry, particularly in Northern Europe. Specializing in private equity strategies such as secondary direct investments, later-stage funding, industry consolidation, add-on acquisitions, growth capital, buyouts, and turnarounds, it targets unlisted small to medium-sized firms in healthcare equipment, services, biotechnology, life sciences, pharmaceuticals, med tech, and assistive technology. The company operates through three core business areas: Assistive Tech, MedTech, and Specialty Pharma, with key holdings including Abilia for cognitive and communication aids, Unimedic for specialty pharmaceuticals and contract manufacturing, Inpac for packaging solutions, and others like Huka, SurgiCube, and Multi ply. Founded in 2001 and headquartered in Stockholm, MedCap acts as an active, long-term owner, providing capital, expertise, networks, and strategic support to enhance profitability and international growth potential in these specialized sectors.
kr 43.08
kr 0.04 (-0.09%)
Live · 10:50 PM · Twelve Data
13.70% operating margin is respectable but not wide. ROIC at 12.29%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 16.7%, still solid.
Even for strong businesses, today's 3x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
2.9x earnings, 2.4x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 2.17B
▲ +16.7% YoY
Net Income (TTM)
kr 226M
▲ +5.5% YoY
Op. Margin
14.06%
▲ +0.4pp YoY
ROIC
12.29%
▼ -0.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 275M
▼ -4.5% YoY
Op. Cash Flow (TTM)
kr 277M
▼ -9.0% YoY
Net Debt
kr 113M
Cash & Equiv.
kr 370M
3Y CAGR: +23.8%
3Y CAGR: +89.5%
Continue Research
At a P/E of 2.9 and a price-to-free-cash-flow of 2.4, MedCap AB (publ) (MCAP.XSTO) trades below a two-stage DCF intrinsic value of about SEK 915.38 per share, so at SEK 43.08 the stock looks undervalued (2,024.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, MedCap AB (publ) scores 87/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 915.38 per share for MCAP.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 686.53. At today's SEK 43.08, that puts the stock about 2,024.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
MedCap AB (publ) scores 87 out of 100 on Intrinsiqq's quality score, passing 6 of 8 checks, which makes it a high-quality business on these measures. Recent fundamentals include a 14.1% operating margin and a 12.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. MCAP.XSTO currently trades below its estimated intrinsic value and scores 87/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.